Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine
Published in: Internal and Emergency Medicine 3/2015

01-04-2015 | IM - ORIGINAL

Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis

Authors: Tarang Taghvaei, Iradj Maleki, Farshad Nagshvar, Hafez Fakheri, Vahid Hosseini, Seyed Mohammad Valizadeh, Hassan Neishaboori

Published in: Internal and Emergency Medicine | Issue 3/2015

Login to get access

Abstract

Ulcerative colitis (UC) is a chronic, idiopathic, inflammatory large bowel disease with recurrent variable periods of exacerbation. The aim of the current study is to evaluate the correlation of UCEIS with fecal calprotectin (FC) level to assess disease activity in UC patients in order to determine whether FC can prognosticate clinical outcome and disease activity of UC instead of colonoscopic evaluation. Our endoscopic investigations revealed the extension of UC as the following: proctitis (11.6 %), procto-sigmoiditis (18.5 %), left-sided colitis (15.8 %), extensive colitis (11.7 %), and normal endoscopy (42.4 %). Conclusively, we suggest that FC can be used as a reliable tool to evaluate disease activity in ulcerative colitis patients. Moreover, our findings indicate a significant correlation between FC level and mucosal healing.
Literature
1.
Langhorst J, Elsenbruch S, Mueller T et al (2005) Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 11(12):1085–1091CrossRefPubMed
2.
Fefferman DS, Farrell RJ (2005) Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol: the official clinical practice journal of the American Gastroenterological Association. 3(1):11–24CrossRef
3.
Schoepfer AM, Beglinger C, Straumann A et al (2009) Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 15(12):1851–1858CrossRefPubMed
4.
Angriman I, Scarpa M, D’Inca R et al (2007) Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta; International Journal Of Clinical Chemistry. 381(1):63–68CrossRef
5.
Travis SP, Schnell D, Krzeski P et al (2013) Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 145(5):987–995CrossRefPubMed
6.
Walsh AJ, Ghosh A, Brain AO et al (2014) Comparing disease activity indices in ulcerative colitis. J Crohns Colitis 8(4):318–325
7.
Carpenter HA, Talley NJ (2000) The importance of clinicopathological correlation in the diagnosis of inflammatory conditions of the colon: histological patterns with clinical implications. Am J Gastroenterol 95(4):878–896CrossRefPubMed
8.
Nikolaus S, Schreiber S (2007) Diagnostics of inflammatory bowel disease. Gastroenterology 133(5):1670–1689CrossRefPubMed
9.
10.
Desai D, Faubion WA, Sandborn WJ (2007) Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 25(3):247–255CrossRefPubMed
11.
Gisbert JP, Gonzalez-Lama Y, Mate J (2007) Role of biological markers in inflammatory bowel disease. Gastroenterol Hepatol 30(3):117–129CrossRefPubMed
12.
Tibble JA, Sigthorsson G, Bridger S et al (2000) Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119(1):15–22CrossRefPubMed
13.
Tibble JA, Bjarnason I (2001) Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 7(4):460–465PubMed
14.
Bitton A, Peppercorn MA, Antonioli DA et al (2001) Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 120(1):13–20CrossRefPubMed
15.
Sutherland AD, Gearry RB, Frizelle FA (2008) Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 51(8):1283–1291CrossRefPubMed
16.
Geboes K, Riddell R, Ost A et al (2000) A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47(3):404–409CrossRefPubMedCentralPubMed
17.
Bjerke K, Halstensen TS, Jahnsen F et al (1993) Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer’s patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 34(10):1357–1363CrossRefPubMedCentralPubMed
18.
Costa F, Mumolo MG, Ceccarelli L et al (2005) Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 54(3):364–368CrossRefPubMedCentralPubMed
19.
20.
Konikoff MR, Denson LA (2006) Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 12(6):524–534CrossRefPubMed
21.
Xiang JY, Ouyang Q, Li GD et al (2008) Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 14(1):53–57CrossRefPubMedCentralPubMed
22.
Langhorst J, Elsenbruch S, Koelzer J et al (2008) Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 103(1):162–169CrossRefPubMed
23.
Canani RB, Terrin G, Rapacciuolo L et al (2008) Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 40(7):547–553CrossRef
24.
Silberer H, Kuppers B, Mickisch O et al (2005) Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 51(3–4):117–126PubMed
25.
Gisbert JP, McNicholl AG (2009) Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 41(1):56–66CrossRef
26.
Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R et al (2010) Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis 4(2):144–152CrossRefPubMed
27.
D’Haens G, Sandborn WJ, Feagan BG et al (2007) A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132(2):763–786CrossRefPubMed
28.
Naganuma M, Ichikawa H, Inoue N et al (2010) Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol 45(9):936–943CrossRefPubMed
29.
Travis SP, Schnell D, Krzeski P et al (2012) Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 61(4):535–542CrossRefPubMedCentralPubMed
30.
Rachmilewitz D (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298(6666):82–86CrossRefPubMedCentralPubMed
31.
32.
Gisbert JP, Bermejo F, Perez-Calle JL et al (2009) Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 15(8):1190–1198CrossRefPubMed
33.
Kaiser T, Langhorst J, Wittkowski H et al (2007) Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 56(12):1706–1713CrossRefPubMedCentralPubMed
Metadata
Title
Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis
Authors
Tarang Taghvaei
Iradj Maleki
Farshad Nagshvar
Hafez Fakheri
Vahid Hosseini
Seyed Mohammad Valizadeh
Hassan Neishaboori
Publication date
01-04-2015
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue 3/2015
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-014-1144-x

Other articles of this Issue 3/2015

Internal and Emergency Medicine 3/2015 Go to the issue

IM - ORIGINAL

The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy

HTA-ORIGINAL

The Italian MacNew heart disease health-related quality of life questionnaire: a validation study

CE - LETTER TO THE EDITOR

Variability in the benefit of the novel oral anticoagulant agents in patients with non-valvular atrial fibrillation

CE - MEDICAL ILLUSTRATION

Clinical evolution, management, and resolution of type II necrotizing fasciitis

DEBATE

Is there still a place for thrombolytic therapy in hemodynamically stable patients with acute pulmonary embolism? No

CE - COMMENTARY

Out of the blue: the Grey-Turner's sign
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits